A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial

NCT03183934 · clinicaltrials.gov ↗

COMPLETED

Status

2

Enrollment

INDUSTRY

Sponsor class

Conditions

Dystrophic Epidermolysis Bullosa

Interventions

BIOLOGICAL: ALLO-ASC-DFU

Sponsor

Anterogen Co., Ltd.